← Leaderboards
Neil Desai
Aadi, Llc
$3,564,498
Attributed
$3,564,498
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $924.7K · FY2012–20$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
FDA$1,998,524 · 1
NIH$1,565,974 · 1
By mechanism
R01$1,998,524 · 1
R42$1,565,974 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Antigen Presentation”
- Jeffrey P Krischer · University Of South Florida$69,250,624
- Constance Ann Benson · University Of California, San Diego$65,790,143
- David Heimbrook · Leidos Biomedical Research, Inc.$56,453,265
- Ellis L Reinherz · Dana-Farber Cancer Institute$37,262,008
- Emil R Unanue · Washington University$29,036,066
- Mitchell Kronenberg · Cedars-Sinai Medical Center$27,802,337
Research focus
Antigen PresentationDrug KineticsBaseBinding (Molecular Function)AutophagocytosisAlbuminsBladderBladder TissueBloodCalmette-Guerin BacillusCancer ModelCancer PatientCessation Of LifeClinical EfficacyClinical ResearchClinical TrialsCohortCostCystoscopyCytotoxic ChemotherapyDisease ProgressionDoseDrug ExposureEnrollment
Grant awards (7)
Phase 2 study of ABI-009 Treatment of Advanced PEComa-IND 125669, 7/13/2015$499,631
R01 · FY2020 · FD · contact PI
Phase 2 study of ABI-009 Treatment of Advanced PEComa-IND 125669, 7/13/2015$499,631
R01 · FY2019 · FD · contact PI
Phase 2 study of ABI-009 Treatment of Advanced PEComa-IND 125669, 7/13/2015$499,631
R01 · FY2018 · FD · contact PI
Phase 2 study of ABI-009 Treatment of Advanced PEComa-IND 125669, 7/13/2015$499,631
R01 · FY2017 · FD · contact PI
Investigation of a nanoparticle albumin-bound mTOR inhibitor, nab-rapamycin for t$924,745
R42 · FY2015 · CA · contact PI
Investigation of a nanoparticle albumin-bound mTOR inhibitor, nab-rapamycin for t$168,928
R42 · FY2013 · CA · contact PI
Investigation of a nanoparticle albumin-bound mTOR inhibitor, nab-rapamycin for t$472,301
R42 · FY2012 · CA · contact PI